Scientific advisors
Prof. Thomas Matthes
Dr. Matthes is Professor at the Hematology Service at the University of Geneva. He studied medicine at the Universities of Ulm (Germany), Lausanne and Geneva. After obtaining his doctorate, he spent three years as a post-doc at the Pasteur Institute in Paris, before specializing in Internal Medicine and later in Hematology. Since 2003 he holds a senior position (Médecin Adjoint) at the Hematology Service. His scientific work focuses on the role of adhesion molecules in the pathophysiology of lymphoproliferative syndromes and on the development of new biomarkers for the diagnosis of these diseases. From 2010 to 2013 Dr. Matthes was President of the Swiss Flow Cytomery Society and in 2012 he founded the Swiss Flow Cytometry School and is its current director.
Dr. Matthes is Professor at the Hematology Service at the University of Geneva. He studied medicine at the Universities of Ulm (Germany), Lausanne and Geneva. After obtaining his doctorate, he spent three years as a post-doc at the Pasteur Institute in Paris, before specializing in Internal Medicine and later in Hematology. Since 2003 he holds a senior position (Médecin Adjoint) at the Hematology Service. His scientific work focuses on the role of adhesion molecules in the pathophysiology of lymphoproliferative syndromes and on the development of new biomarkers for the diagnosis of these diseases. From 2010 to 2013 Dr. Matthes was President of the Swiss Flow Cytomery Society and in 2012 he founded the Swiss Flow Cytometry School and is its current director.
Dr Isaac Kobrin
Dr. Kobrin is an internist educated in Israel with further training (Fullbright Fellowship) at the Ochsner Medical Foundation in New Orleans, LA, USA. In 1989, he joined Hoffmann-La Roche and was responsible for the worldwide clinical development of key compounds within the company's cardiovascular portfolio (from Phase 1 to marketing approval). In 1999, he joined Actelion as Senior Vice President, head of clinical development and member of the Executive Committee. He later was appointed to Chief Medical Officer at Actelion. During his 22 years in the pharma industry, 3 drugs were approved under his leadership, and he was directly involved in numerous regulatory interactions with the US-FDA and the European EMEA/CHMP. In addition, Dr. Kobrin was actively involved in investor relations and business development.
Dr. Kobrin is an internist educated in Israel with further training (Fullbright Fellowship) at the Ochsner Medical Foundation in New Orleans, LA, USA. In 1989, he joined Hoffmann-La Roche and was responsible for the worldwide clinical development of key compounds within the company's cardiovascular portfolio (from Phase 1 to marketing approval). In 1999, he joined Actelion as Senior Vice President, head of clinical development and member of the Executive Committee. He later was appointed to Chief Medical Officer at Actelion. During his 22 years in the pharma industry, 3 drugs were approved under his leadership, and he was directly involved in numerous regulatory interactions with the US-FDA and the European EMEA/CHMP. In addition, Dr. Kobrin was actively involved in investor relations and business development.
